A Multi-centre, Open, Prospective, Randomized, Parallel-group, 24-month Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (\> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression at 6 months. The main question this study aims to answer is: Does maintaining long-term immunosuppression in patients with a late renal graft failure (\> 3 months) safely reduce the risk of HLA sensitization? To answer this question, patients will be assigned to a control arm or investigational arm: * Patients assigned to the control arm will receive standard treatment, in which immunosuppressant treatment is withdrawn after 6 months. * Patients assigned to the investigatonal arm will continue immunosuppressant treatment at low doses for 2 years. Patients recruited in this clinical trial will be followed for up to 2 years. During this time, patients will visit the clinic every 3 months for checkups and tests.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient must be able to understand and provide written informed consent

• Patients older than 18 years who had received at least one previous renal transplant

• Patients with a retained kidney graft failed for any reason which survived at least 3 months

• Patients on dialysis, either hemodialysis or peritoneal dialysis. Patients can be on dialysis for a maximum of 6 months at the time of randomization, as long as the patients have taken an uninterrupted immunosuppressive regimen of calcineurin inhibitors (tacrolimus or cyclosporine) and steroids since dialysis was restarted

• Patients already relisted or candidates to relist to deceased donor kidney transplantation according to the treating physician criteria

• Patients taking immunosuppressants tacrolimus or cyclosporine

• cPRA at the time of randomization ≤ 90%

Locations
Other Locations
Spain
Hospital Universitario Vall D'Hebron
RECRUITING
Barcelona
Contact Information
Primary
Francesc Moreso, MD, PhD
francescjosep.moreso@vallhebron.cat
93 489 30 00
Time Frame
Start Date: 2024-01-22
Estimated Completion Date: 2028-01-31
Participants
Target number of participants: 202
Treatments
Active_comparator: Control Arm
Active_comparator: Investigational arm
Related Therapeutic Areas
Sponsors
Leads: Hospital Universitari Vall d'Hebron Research Institute

This content was sourced from clinicaltrials.gov

Similar Clinical Trials